Disruptive Pharma AB (publ)

kr 0.98As of Sun 8 Nov 2026, 12:00 UTC

STO:DPHAHealthcare

Country Sweden

PE (Fwd) —

TSR 10Y CAGR —

Div yield —

ROE (161.81%)

Drug Manufacturers (General)

Beta (5Y) —

PE TTM —

TSR TTM —

Mkt cap kr 43.83M

ROIC —

SE Grade™

—

Value

Quality

Moat

—

1Y Price

Reference

kr 1.05

7.11%

(69.59%)

Price above Reference Value

TTM

FYE 31 Dec SEK

FY2024

FY2025

FY2026E

Trend

10Y

Peers

0.877

Revenuekr M

—

◌—

0.877

—

Revenue growth%

—

100.00

Gross margin%

—

100.00

—

(2291.68)

Operating margin%

—

(2291.68)

(100.00)

(2291.68)

—

(2272.98)

Net margin%

—

(2272.98)

(100.00)

(2272.98)

—

P/E ratio (avg)x

—

EV/EBITx

—

(47.18)

FCF yield (avg)%

—

(1.99)

—

(2370.24)

FCF margin%

—

(2370.24)

(100.00)

(2370.24)

—

1.043

FCF / Net incomex

—

0.988

1.043

—

1.015

—

ROIC%

—

(34.48)

—

(161.81)

Return on equity%

—

(167.85)

(161.81)

(13.69)

(164.83)

—

(200.79)

Return on assets%

—

(132.81)

(200.79)

(10.13)

(166.80)

—

(0.44)

EPSkr

—

(0.67)

(0.44)

(0.02)

—

33.26

EPS growth%

—

33.26

95.60

33.26

—

0.15

Bookvalue per shkr

—

0.40

0.15

0.13

(61.53%)

—

(0.46)

FCF per sharekr

—

(0.66)

(0.46)

(0.02)

—

Dividend per shkr

—

Div yield (avg)%

—

Payout ratio%

—

44.59

Shares (diluted)M

—

44.82

◌44.82

—

Buyback yield%

—

◌—

—

D/E ratiox

—

36.10

Enterprise valuekr M

—

36.33

—

LT debtkr M

—

Peers (US$4.373M)

Cap (US$)

KDventures AB

10.74M

—

Fluicell AB (publ)

3.889M

13.77x

NextCell Pharma AB

3.597M

—

Tecnovatica S.A.

3.814M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

(6,699)

(7,168)

Own earn%

—

Sh yield%

—

Owners

Insiders/Inst%

—

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

—

Revenue growth years

—

EPS growth years

—

Dividend streakyrs

—

Op margin range%

—

$1 testx

—

Incr. ROIC%

—

Disruptive Pharma AB (publ) operates as a pharmaceutical technology company in Sweden. The company develops and commercializes Formulite, a patented and clinically evaluated platform technology for oral drug formulation and drug product development. The company is based in Stockholm, Sweden.

Growth vs revenue

Latest

Trend

CAGR

Rel growth

Revenue

kr 0.877M

Operating expenses

kr 20.98M

Asset mix

Trend

Cash and investments

77.82%

Other

22.18%

Reinvestment returns

No breakdown available